VIA EDGAR AND FACSIMILE
December 20, 2016
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Susan Hayes
Re: Voyager Therapeutics, Inc.
Acceleration Request for Registration Statement on Form S-3
File No. 333-214861
Dear Ms. Hayes,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), Voyager Therapeutics, Inc. (the Company) hereby requests that the effective date of the above-referenced registration statement (the Registration Statement) be accelerated to December 20, 2016, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Edwin OConnor at (212) 813 8853. We also respectfully request that a copy of the written order from the Securities and Exchange Commission (the Commission) verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Edwin OConnor, by facsimile to (212) 937 3476.
If you have any questions regarding this request, please contact Edwin OConnor of Goodwin Procter LLP at (212) 813 8853.
|
Sincerely, | |
|
| |
|
VOYAGER THERAPEUTICS, INC. | |
|
| |
|
| |
|
/s/ Steven M. Paul | |
|
Steven M. Paul, M.D. | |
|
President and Chief Executive Officer | |
|
| |
|
| |
|
cc: |
J. Jeffrey Goater, Voyager Therapeutics, Inc. |
|
|
Mitchell S. Bloom, Goodwin Procter LLP |
|
|
Edwin OConnor, Goodwin Procter LLP |
|
|
Laurie A. Burlingame, Goodwin Procter LLP |